PARSIPPANY, N.J., Nov. 7, 2022 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, manufacturer of the CONTOUR® portfolio of blood glucose monitoring (BGM) systems, and system distributor Eversense® continuous glucose monitoring (CGM) app, announces that the Eversense® CGM app has been updated globally to seamlessly integrate with Apple HealthTM. This means that people with diabetes using Eversense CGM systems will now also have the option to view their glucose data within the Apple Health app, along with other health metrics on the iPhone's widely used health and wellness platform.
Developed by Senseonics Holdings, Inc. (NYSE American: SENS), the exceptionally accurate and fully implantable Eversense E3 is the longest-lasting CGM on the market, with a sensor life of up to 6 months. The system transmits the data to the Eversense CGM app, where users can easily view, analyze and share glucose data, and receive alerts on changes and trends. With this update, users in all markets where Eversense is available can choose to view their data in Apple Health, where they will also be able to view health data collected by their iPhone across various apps and devices. This integration is intended to improve diabetes management by allowing Eversense users to easily view their glucose data within their broader digital health environment.
"We are excited to integrate the Eversense CGM system with Apple HealthTM, giving our users more options on how to view and use the data to manage their diabetes," said Elaine Anderson, Eversense CGM Business Unit Manager at Ascensia Diabetes. Care. "Complementing the benefits of the Eversense CGM app, this update enables people with diabetes to access glucose data along with other important metrics to provide a more holistic view of their health and wellness. In an increasingly digital world, it is It is important for medical devices and digital solutions to be interoperable, and we are excited to further integrate Eversense into the connected healthcare ecosystem."
Ascensia Diabetes Care is committed to putting the power of advanced information, data and analytics in the hands of patients and is working with Senseonics to make Eversense interoperable with more digital diabetes devices and platforms. Together, the companies are executing plans to achieve iCGM (integrated CGM) approval and integration with automatic insulin delivery (AID) systems, as well as actively pursuing industry collaborations that maximize the benefits of Eversense for the diabetes community.
Eversense CGM Systems and the Eversense CGM App are available in the US and Europe. For more information, visit www.ascensia.com/eversense.
logo - link
View original content: enlace